DouglasRS, GuptaS. The pathophysiology of thyroid eye disease: implications for immunotherapy. Curr Opin Ophthalmol2011;22(5):385-390; doi: 10.1097/ICU.0b013e3283499446.
2.
RachmasariKN, Toro-TobonD, WagnerLH, et al.Impact of teprotumumab on clinical practice in thyroid eye disease. Endocr Pract2024;30(10):937-942; doi: 10.1016/j.eprac.2024.06.010.
3.
Toro-TobonD, StanMN. The evolving landscape of thyroid eye disease: present and future. Eur J Endocrinol2025;193(2):R15-R24; doi: 10.1093/ejendo/lvaf156.
4.
StanMN, KriegerCC. The adverse effects profile of teprotumumab. J Clin Endocrinol Metab2023;108(9):e654-e662; doi: 10.1210/clinem/dgad213.
5.
KahalyGJ, DouglasRS, HoltRJ, et al.Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials. Lancet Diabetes Endocrinol2021;9(6):360-372; doi: 10.1016/s2213-8587(21)00056-5.
HaSK, LinLY, ChiouCA, et al.Longitudinal glycemic outcomes in patients with thyroid eye disease treated with teprotumumab. Ophthalmic Plast Reconstr Surg. Epub2025 Dec 2; doi: 10.1097/iop.0000000000003126.
